Phase II study: Active specific immunotherapy with the 1e10 anti idiotype vaccine in the treatment of patients with advanced non small cell lung cancer

Trial Profile

Phase II study: Active specific immunotherapy with the 1e10 anti idiotype vaccine in the treatment of patients with advanced non small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Racotumomab (Primary) ; Alum
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2014 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 02 Oct 2012 Status changed from active, no longer recruiting to completed.
    • 02 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top